← Back to Analyst Consensus 
CHRS Buy
Coherus Oncology, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 11, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Jan 22, 2026 | Oppenheimer | initiate | — → Outperform | $10 | 52% |
| Sep 4, 2025 | Maxim Group | upgrade | Hold → Buy | $4 | 42% |
| Apr 29, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Apr 24, 2025 | UBS | maintain | Neutral → Neutral | $1.05 | 54% |
| Mar 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Jan 23, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Jan 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Dec 5, 2024 | Baird | maintain | Outperform → Outperform | $6 | 55% |
| Dec 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Nov 8, 2024 | Baird | maintain | Outperform → Outperform | $4 | 55% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Sep 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Aug 16, 2024 | UBS | downgrade | Buy → Neutral | $1.5 | 54% |
| Aug 5, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Jul 1, 2024 | Baird | maintain | Outperform → Outperform | $8 | 55% |
| May 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| May 13, 2024 | Truist Securities | maintain | Buy → Buy | $7 | 54% |
| May 10, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Mar 20, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Mar 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Jan 23, 2024 | Baird | maintain | Outperform → Outperform | $9 | 55% |
| Jan 23, 2024 | Truist Securities | maintain | Buy → Buy | $8 | 54% |
| Dec 27, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Dec 7, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Nov 28, 2023 | Truist Securities | reiterate | Buy → Buy | $12 | 54% |
| Nov 17, 2023 | Baird | initiate | — → Outperform | $11 | 55% |
| Nov 8, 2023 | Maxim Group | downgrade | Buy → Hold | $0 | 42% |
| Nov 7, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Oct 23, 2023 | Barclays | maintain | Overweight → Overweight | $7 | 53% |
| Sep 26, 2023 | Truist Securities | reiterate | Buy → Buy | $20 | 54% |
| Sep 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Aug 3, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Jul 24, 2023 | Citigroup | initiate | — → Buy | $12 | 54% |
| Jul 14, 2023 | Truist Securities | maintain | Buy → Buy | $20 | 54% |
| Jun 28, 2023 | Truist Securities | reiterate | Buy → Buy | $22 | 54% |
| Jun 20, 2023 | Truist Securities | maintain | Buy → Buy | $22 | 54% |
| Jun 20, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $24 | 44% |
| Jun 15, 2023 | Truist Securities | reiterate | Buy → Buy | $24 | 54% |
| Jun 6, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $24 | 44% |
| Jun 1, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $24 | 44% |
| May 23, 2023 | Barclays | maintain | Overweight → Overweight | $8 | 53% |
| May 9, 2023 | HC Wainwright & Co. | maintain | — → Buy | $24 | 44% |
| May 1, 2023 | Truist Securities | initiate | — → Buy | $24 | 54% |
| Mar 28, 2023 | UBS | upgrade | Neutral → Buy | $11 | 54% |
| Mar 8, 2023 | Barclays | maintain | — → Overweight | $13 | 53% |
| Mar 7, 2023 | HC Wainwright & Co. | maintain | — → Buy | $26 | 44% |
| Nov 16, 2022 | Mizuho | maintain | — → Buy | $21 | 52% |
| Nov 14, 2022 | JP Morgan | maintain | — → Neutral | $11 | 54% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days